23rd July, 2026

(1) BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026

Dear Sir / Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today i.e., 23rd July, 2026, has *inter-alia* approved the unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2026.

In this regard, please find enclosed the following for the quarter ended 30th June, 2026:

- Unaudited financial results (standalone and consolidated) as per Indian Accounting Standards; and
- Limited review report (standalone and consolidated) issued by M/s B S R & Co. LLP, Statutory Auditors of the Company

The Board meeting of the Company commenced today at 09:15 a.m. (IST) and is still in progress. The conclusion time of meeting will be separately intimated to the Stock Exchanges upon completion of proceedings.

The above-mentioned documents will also be available on the Company's website www.cipla.com in the Investors Section.

Kindly take the above information on record.

Yours faithfully,
For Cipla Limited
RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.07.23 11:43:34 +05'30'

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Neelam Padwad

Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 41916000 **W** www.cipla.com **E-mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

Cipla

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(₹ in Crores)

Particulars	Quarter ended			Year ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited (Refer Note 10)	Unaudited	Audited
1. Revenue from operations				
a) Revenue from sale of products (refer note 9)	**7,077.02**	6,464.26	6,837.04	27,711.69
b) Other operating revenue	**42.26**	76.94	120.43	450.90
Total revenue from operations	**7,119.28**	**6,541.20**	**6,957.47**	**28,162.59**
2. Other income	**210.90**	148.16	258.56	882.01
3. Total income (1+2)	**7,330.18**	**6,689.36**	**7,216.03**	**29,044.60**
4. Expenses				
a) Cost of materials consumed	**1,356.93**	1,382.15	1,469.35	5,841.62
b) Purchases of stock-in-trade	**1,251.70**	1,284.73	1,025.02	4,451.37
c) Changes in inventories of finished goods, work-in-progres and stock-in-trade	**58.55**	(418.20)	(323.66)	(743.88)
d) Employee benefits expense	**1,497.41**	1,414.25	1,312.30	5,366.33
e) Finance costs	**17.03**	13.13	14.05	54.39
f) Depreciation, impairment and amortisation expense	**304.24**	382.92	252.72	1,210.98
g) Impairment of investment in associates (refer note 7)	-	42.02	-	42.02
h) Other expenses (refer note 9)	**1,762.39**	1,881.30	1,696.32	7,322.23
Total expenses	**6,248.25**	**5,982.30**	**5,446.10**	**23,545.06**
5. Profit before exceptional items, tax and share of profit/(loss) from associates (3-4)	**1,081.93**	**707.06**	**1,769.93**	**5,499.54**
6. Exceptional item - (Loss) (refer note 4)	-	-	-	**(275.91)**
7. Profit before tax and share of profit/(loss) from associates (5+6)	**1,081.93**	**707.06**	**1,769.93**	**5,223.63**
8. Tax expense/ (credit) (net)				
a) Current tax	**392.78**	282.17	529.55	1,440.95
b) Deferred tax	**(97.95)**	(125.22)	(51.67)	(87.11)
Total tax expense (net)	**294.83**	**156.95**	**477.88**	**1,353.84**
9. Net profit after tax before share of profit/(loss) from associates (7-8)	**787.10**	**550.11**	**1,292.05**	**3,869.79**
10. Share of profit (+)/loss (-) of associates	**(1.55)**	**(7.60)**	**(0.44)**	**(8.05)**
11. Net profit for the period/year (9+10)	**785.55**	**542.51**	**1,291.61**	**3,861.74**
12. Profit for the period/year attributable to				
a) Owners of the parent	**789.05**	**554.64**	**1,297.62**	**3,879.23**
b) Non - controlling interest	**(3.50)**	(12.13)	(6.01)	(17.49)
13. Other comprehensive income/(loss) for the period/year				
a) (i) Items that will not be reclassified to profit or loss	**24.25**	(177.96)	(8.54)	(188.93)
(ii) Income tax on items that will not be reclassified to profit or loss	**(6.10)**	(0.69)	2.15	2.07
b) (i) Items that will be reclassified to profit or loss	**188.74**	301.97	86.09	828.14
(ii) Income tax on items that will be reclassified to profit or loss	**(12.83)**	12.47	1.71	46.46
Total other comprehensive income/(loss) for the period/year	**194.06**	**135.79**	**81.41**	**687.74**
14. Total comprehensive income for the period/year (11+13)	**979.61**	**678.30**	**1,373.02**	**4,549.48**
15. Total comprehensive income/(loss) attributable to				
a) Owners of the parent	**982.62**	**692.07**	**1,378.82**	**4,567.92**
b) Non - controlling interest	**(3.01)**	(13.77)	(5.80)	(18.44)
16. Paid-up equity share capital (face value of ₹ 2/- each) (refer note 3)	**161.57**	**161.56**	**161.55**	**161.56**
17. Other equity				34,270.39
18. Earnings per equity share (face value of ₹ 2/- each)				
a) Basic (₹)	***9.77**	*6.87	*16.07	48.03
b) Diluted (₹)	***9.76**	*6.86	*16.06	48.00
*Not Annualised				

1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. The National Pharmaceutical Pricing Authority ("NPPA") issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 ("DPCO").

   In 1999 and 2000, the Company filed writ petitions before the Hon'ble Bombay High Court ("Bombay HC") challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon'ble Supreme Court ("SC").

   On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC's Judgment the Company deposited an amount of ₹ 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003.

   Post 2003, the Company continued to receive demands ("Subsequent demands") alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India's RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC's TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands.

   The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company's position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July, 2025 the Company has voluntarily deposited with the NPPA an additional amount of ₹ 27.07 Crores towards the principal against certain demand notices.

   The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to ₹ 2,011 Crores with the principal of ₹ 863 Crores and interest of ₹ 1,148 Crores.

   The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively "Okasa"), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to ₹ 9.96 Crores), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla's subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon'ble Bombay HC.

   The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa.

3. The paid-up equity share capital stands increased to ₹ 161.57 Crores (80,78,45,316 equity shares of face value ₹ 2 each) upon allotment of 54,903 equity shares and 7,782 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" and "Cipla ESAR Scheme 2021" respectively during the quarter ended 30th June, 2026.

4. Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. Pursuant to the Group's assessment performed as at 31st December, 2025, the Group recognized an incremental gratuity liability arising from past service cost and an increase in leave liability aggregating ₹275.91 Crores, primarily due to the revised definition of "wages" applicable to employees and contract labour. Considering the materiality and non-recurring nature of this change, the Group has presented such incremental expenses under "Exceptional Item" in the financial results.

5. The unaudited standalone financial results for the quarter ended 30th June, 2026 are available on the Company's website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com.

6. Operating segment information is presented in a manner consistent with the internal reporting reviewed by the Group's Chief Operating Decision Maker ("CODM") for the purpose of allocating resources and assessing performance. The CODM of the Group is the Chief Executive Officer, who is responsible for making strategic decisions.

   During the year ended 31st March 2026, the Group reassessed its operating segments consequent to a change in the CODM. Based on this reassessment, the Group has determined that it operates as a single operating segment, namely Pharmaceutical and related products. Accordingly, the comparative information for the previous year has been restated, wherever necessary, to reflect the Group as operating under a single reportable segment, in accordance with Ind AS 108 – Operating Segments.

7. During the quarter and year ended 31st March 2026, the group has recorded an impairment of ₹ 42.02 Crores in the financial results in respect of associates, on account of change in certain business conditions and market dynamics.

8. The Board of Directors of the Company, at its meeting held on 19th March 2026, approved the Scheme of Amalgamation of Inzpera Healthsciences Limited, a wholly owned subsidiary of the Company (the "Transferor Company"), with Cipla Limited (the "Transferee Company" or the "Company"). The Scheme of Amalgamation is subject to the necessary approvals required under the Companies Act, 2013, including the approval of the Hon'ble National Company Law Tribunal ("NCLT"), Mumbai. The Company has filed the Scheme with the Hon'ble NCLT and its approval is awaited.

9. Effective 1st April, 2026, the Group presents certain marketing and promotional expenditures as a reduction from Revenue from Operations. The Group believes that this presentation provides more relevant information on the Group's financial performance. In the comparative periods, these amounts were presented under Sales promotion expenses within Other Expenses and amounted to ₹ 115.24 Crores, ₹ 145.13 Crores and ₹ 528.29 Crores for the quarter ended 30th June, 2025, quarter ended 31st March, 2026 and year ended 31st March, 2026, respectively. This change relates solely to presentation and has no impact on Profit for the period/year, Earnings per Share, Total Equity or Cash Flows

10. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

11. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 23rd July, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

For and on behalf of the Board
For **CIPLA LIMITED**

Achin Gupta
Digitally signed by Achin Gupta
Date: 2026.07.23 11:06:02 +05'30'

Mumbai
23rd July, 2026

Achin Gupta
Managing Director and Global Chief Executive Officer
DIN: 09491674

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Cipla Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Cipla Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Cipla Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its associates for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The consolidated financial results of the Group and its associates for the year ended 31 March 2026 were audited by the predecessor auditor whose report dated 13 May 2026 had expressed an unmodified opinion. The consolidated financial results of the Group and its associates for the corresponding quarter ended 31 March 2026 were reviewed by the predecessor auditor whose report dated 13 May 2026 had expressed an unmodified conclusion.

8. The consolidated financial results of the Group and its associates for the three months ended 30 June 2025 were reviewed by the predecessor auditor whose report dated 25 July 2025 had expressed an unmodified conclusion.

9. We did not review the interim financial information of Fourteen (14) Subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 878.87 Crores, total net loss after tax (before consolidation adjustments) of Rs. 34.33 Crores and total comprehensive loss (before consolidation adjustments) of Rs. 43.75 Crores, for the quarter ended 30 June 2026, as considered in the Statement. The Statement also include the Group's share of net profit after tax of Rs. 0.23 Crores and total comprehensive income of Rs. 0.23 Crores, for the quarter ended 30 June 2026 as considered in the Statement, in respect of One (1) associate, whose interim financial information have not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Certain of these subsidiaries and associate are located outside India whose interim financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial information of such subsidiaries and associate located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries and associate located outside India is based on the reports of other auditors and the conversion adjustments prepared by the management of the Parent and reviewed by us.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sudhir Murlidhar Soni

Digitally signed by Sudhir Murlidhar Soni
Date: 2026.07.23 11:28:55 +05'30'

Sudhir Soni

Partner

Membership No.: 041870

UDIN:26041870IHHJZD8392

Mumbai

23 July 2026

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of entities	Relationship
1	Cipla Limited (India)	Parent Company
2	Meditab Specialities Limited, India	Subsidiary
3	Medispray Laboratories Private Limited, India	Subsidiary
4	Goldencross Pharma Limited, India	Subsidiary
5	Sitec Labs Limited, India	Subsidiary
6	Cipla Health Limited, India	Subsidiary
7	Cipla Pharma and Life Sciences Limited, India	Subsidiary
8	Cipla Pharmaceuticals Limited, India	Subsidiary
9	Inzpera Healthsciences Limited.,India (acquired w.e.f 4 December 2025), India	Subsidiary
10	Jay Precision Pharmaceuticals Private Limited, India	Subsidiary
11	Cipla Health Employees Stock Option Trust, India	Subsidiary
12	Cipla Digital Health Limited, India	Subsidiary
13	Cipla Medpro South Africa (Pty) Limited, South Africa	Subsidiary
14	Cipla Medpro Manufacturing (Pty) Limited, South Africa	Subsidiary
15	Cipla-Medpro (Pty) Limited, South Africa	Subsidiary
16	Cipla-Medpro Distribution Centre (Pty) Limited, South Africa	Subsidiary
17	Cipla Medpro Botswana (Pty) Limited, Botswana	Subsidiary

	18	Cipla Kenya Limited, Kenya		Subsidiary	
	19	Cipla Select (Pty) Limited, South Africa		Subsidiary	
	20	Medpro Pharmaceutica (Pty) Limited, South Africa		Subsidiary	
	21	Mirren (Pty) Limited, South Africa		Subsidiary	
	22	The Cipla Empowerment Trust, South Africa		Subsidiary	
	23	Actor Pharma (Pty) Limited, South Africa		Subsidiary	
	24	InvaGen Pharmaceuticals Inc., USA		Subsidiary	
	25	Exelan Pharmaceuticals Inc., USA		Subsidiary	
	26	Cipla USA Inc., USA		Subsidiary	
	27	Cipla Therapeutics Inc., USA		Subsidiary	
	28	Aspergen Inc., USA		Subsidiary	
	29	Cipla Holding B.V., Netherlands		Subsidiary	
	30	Cipla (EU) Limited, United Kingdom		Subsidiary	
	31	Cipla Australia Pty Limited, Australia		Subsidiary	
	32	Meditab Holdings Limited, Mauritius		Subsidiary	
	33	Cipla Malaysia Sdn. Bhd., Malaysia		Subsidiary	
	34	Cipla Europe NV, Belgium		Subsidiary	
	35	Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda., Brazil		Subsidiary	
	36	Cipla Algérie, Algeria		Subsidiary	
	37	Breathe Free Lanka (Private) Limited, Sri Lanka		Subsidiary	
	38	Cipla Maroc SA, Morocco		Subsidiary	

	39	Cipla Gulf FZ-LLC, UAE		Subsidiary	
	40	Cipla Colombia SAS, Colombia		Subsidiary	
	41	Cipla (China) Pharmaceutical Co., Ltd., China		Subsidiary	
	42	Cipla (Jiangsu) Pharmaceutical Co., Ltd., China		Subsidiary	
	43	Mexicip S.A. de C.V., Mexico		Subsidiary	
	44	CiplaRna GmbH, Germany (incorporated w.e.f. 28 May 2025)		Subsidiary	
	45	Cipla Middle East Company, Kingdom of Saudi Arabia (incorporated w.e.f. 1 March 2026)		Subsidiary	
	46	Aspergen Limited, India (incorporated w.e.f 5 May 2026)		Subsidiary	
	47	Stempeutics Research Private Limited, India		Associate	
	48	AMPIN Power Systems Private Limited (formerly known as AMPSOLAR Power Systems Private Limited), India		Associate	
	49	AMPIN Energy Green Eleven Private Limited (formerly known as AMP Energy Green Eleven Private Limited), India		Associate	
	50	Clean Max Auriga Power LLP, India		Associate	
	51	GoApptiv Private Limited, India		Associate	
	52	Iconphygital Private Limited, India (Wholly owned subsidiary of GoApptiv Private Limited)		Associate	
	53	MKC Biotherapeutics Inc., USA		Associate	
	54	Pactiv Healthcare Private Limited, India (Wholly owned subsidiary of GoApptiv Private Limited)		Associate	
	55	Achira Labs Pvt. Ltd, India		Associate	
	56	Brandmed (Pty) Limited, South Africa		Associate	

	57	AMPIN Energy C&I Eighteen Private Limited (formerly known as AMP Energy C&I Eighteen Private Limited), India (w.e.f. 28 May 2025)		Associate	
	58	iCaltech Innovations (Private) Limited, India (w.e.f. 26 August 2025)		Associate	

Cipla

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(₹ in Crores)

Particulars	Quarter ended			Year ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited (Refer note 4)	Unaudited	Audited
1. Revenue from Operations				
a) Revenue from sale of products	**4,672.12**	3,840.92	4,501.66	17,094.67
b) Other operating revenue	**405.56**	369.06	544.51	1,885.28
Total revenue from operations	**5,077.68**	**4,209.98**	**5,046.17**	**18,979.95**
2. Other income	**242.75**	**180.22**	**271.07**	**1,122.65**
3. Total income (1+2)	**5,320.43**	**4,390.20**	**5,317.24**	**20,102.60**
4. Expenses				
a) Cost of materials consumed	**1,038.57**	965.58	1,017.77	3,992.34
b) Purchases of stock-in-trade	**651.15**	763.51	547.43	2,587.97
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**21.54**	(352.87)	(143.79)	(596.45)
d) Employee benefits expense	**914.96**	869.24	818.30	3,350.48
e) Finance costs	**5.68**	6.74	5.88	19.30
f) Depreciation, impairment and amortisation expense	**169.39**	218.11	145.69	658.43
g) Impairment of investment in associate (refer note 6)	**-**	31.00	-	31.00
h) Other expenses	**1,365.52**	1,366.41	1,182.01	5,179.22
Total expenses	**4,166.81**	**3,867.72**	**3,573.29**	**15,222.29**
5. Profit before exceptional items and tax (3-4)	**1,153.62**	**522.48**	**1,743.95**	**4,880.31**
6. Exceptional Item - (Loss) (refer note 5)	**-**	-	-	(244.37)
7. Profit before tax (5+6)	**1,153.62**	**522.48**	**1,743.95**	**4,635.94**
8. Tax expense /(credit) (net)				
a) Current tax	**307.89**	119.77	456.04	1,101.90
b) Deferred tax	**(16.43)**	18.07	(15.22)	18.86
Total tax expense (net)	**291.46**	**137.84**	**440.82**	**1,120.76**
9. Net profit after tax for the period/ year (7-8)	**862.16**	**384.64**	**1,303.13**	**3,515.18**
10. Other comprehensive income/(loss) for the period/year				
a) (i) Items that will not be reclassified to profit or loss	**25.15**	(3.09)	(5.84)	(12.60)
(ii) Income tax on items that will not be reclassified to profit or loss	**(6.33)**	0.78	1.47	3.17
b) (i) Items that will be reclassified to profit or loss	**64.76**	(70.92)	0.62	(182.91)
(ii) Income tax on items that will be reclassified to profit or loss	**(16.30)**	17.85	(0.16)	46.04
Total other comprehensive income/(loss) for the period/year	**67.28**	**(55.38)**	**(3.91)**	**(146.30)**
11. Total comprehensive income for the period/year (9+10)	**929.44**	**329.26**	**1,299.22**	**3,368.88**
12. Paid-up equity share capital (face value of ₹ 2/- each) (refer note 3)	**161.57**	**161.56**	**161.55**	**161.56**
13. Other equity				**34,039.55**
14. Earnings per equity share (face value of ₹ 2/- each)				
a) Basic (₹)	***10.67**	***4.76**	***16.13**	**43.52**
b) Diluted (₹)	***10.67**	***4.76**	***16.12**	**43.49**
*Not Annualised				

1. The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. The National Pharmaceutical Pricing Authority ("NPPA") issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 ("DPCO").

   In 1999 and 2000, the Company filed writ petitions before the Hon'ble Bombay High Court ("Bombay HC") challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon'ble Supreme Court ("SC").

   On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC's Judgment the Company deposited an amount of ₹ 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003.

   Post 2003, the Company continued to receive demands ("Subsequent demands") alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India's RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC's TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands.

   The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company's position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July 2025 the Company has voluntarily deposited with the NPPA an additional amount of ₹ 27.07 Crores towards the principal against certain demand notices.

   The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to ₹ 2,011 Crores with the principal of ₹ 863 Crores and interest of ₹ 1,148 Crores.

   The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively "Okasa"), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to ₹ 9.96 Crores), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla's subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon'ble Bombay HC.

   The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa.

3. The paid-up equity share capital stands increased to ₹ 161.57 Crores (80,78,45,316 equity shares of face value ₹ 2 each) upon allotment of 54,903 equity shares and 7,782 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" and "Cipla ESAR Scheme 2021" respectively during the quarter ended 30th June 2026.

4. The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

5. Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. Pursuant to the Company's assessment performed as at 31st December, 2025, the Company recognized an incremental gratuity liability arising from past service cost and an increase in leave liability aggregating ₹244.37 Crores, primarily due to the revised definition of "wages" applicable to employees and contract labour. Considering the materiality and non-recurring nature of this change, the Company has presented such incremental expenses under "Exceptional Item" in the financial results.

6. During the quarter and year ended 31st March, 2026, the Company has recorded an impairment of ₹ 31.00 Crores in the financial results in respect of an associate, on account of change in certain business conditions and market dynamics.

7. The Board of Directors of the Company, at its meeting held on 19th March 2026, approved the Scheme of Amalgamation of Inzpera Healthsciences Limited, a wholly owned subsidiary of the Company (the "Transferor Company"), with Cipla Limited (the "Transferee Company" or the "Company"). The Scheme of Amalgamation is subject to the necessary approvals required under the Companies Act, 2013, including the approval of the Hon'ble National Company Law Tribunal ("NCLT"), Mumbai. The Company has filed the Scheme with the Hon'ble NCLT and its approval is awaited.

8. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 23rd July, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

For and on behalf of the Board
For **CIPLA LIMITED**

Achin Gupta
Digitally signed by Achin Gupta
Date: 2026.07.23 11:06:54 +05'30'

Achin Gupta
Managing Director and Global Chief Executive Officer
DIN: 09491674

Mumbai
23rd July, 2026

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Cipla Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Cipla Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Cipla Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity",* issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The standalone financial results of the Company for the year ended 31 March 2026 were audited by the predecessor auditor whose report dated 13 May 2026 had expressed an unmodified opinion. The standalone financial results of the Company for the corresponding quarter ended 30 June 2025 and the corresponding period from 1 April 2025 to 30 June 2025 were reviewed by the predecessor auditor whose report dated 25 July 2025 had expressed an unmodified opinion.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sudhir Murlidhar Soni

Digitally signed by Sudhir Murlidhar Soni
Date: 2026.07.23 11:29:47 +05'30'

Sudhir Soni

Partner

Membership No.: 41870

UDIN:26041870YFZIJX6330

Mumbai

23 July 2026